Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
McKesson
Merck
Moodys
Boehringer Ingelheim

Last Updated: March 22, 2023

VEKLURY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Veklury, and what generic alternatives are available?

Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are thirteen patents protecting this drug.

This drug has three hundred and one patent family members in forty-six countries.

The generic ingredient in VEKLURY is remdesivir. One supplier is listed for this compound. Additional details are available on the remdesivir profile page.

DrugPatentWatch® Generic Entry Outlook for Veklury

Veklury will be eligible for patent challenges on October 22, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 29, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for VEKLURY
International Patents:301
US Patents:13
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 31
Clinical Trials: 5
Patent Applications: 39
What excipients (inactive ingredients) are in VEKLURY?VEKLURY excipients list
DailyMed Link:VEKLURY at DailyMed
Drug patent expirations by year for VEKLURY
DrugPatentWatch® Estimated Generic Entry Opportunity Date for VEKLURY
Generic Entry Date for VEKLURY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VEKLURY

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mansoura University HospitalPhase 4
PharmaMarPhase 3
ASST Fatebenefratelli SaccoPhase 3

See all VEKLURY clinical trials

Pharmacology for VEKLURY

US Patents and Regulatory Information for VEKLURY

VEKLURY is protected by twenty-four US patents and three FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VEKLURY is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VEKLURY


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG)


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG)

Methods for treating arenaviridae and coronaviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION

Methods for treating arenaviridae and coronaviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG)

Methods for treating arenaviridae and coronaviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG)

Methods for treating arenaviridae and coronaviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION

Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG)

Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION

Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION

Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG)

Methods for treating Arenaviridae and Coronaviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION

Methods for treating Arenaviridae and Coronaviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG)


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALE THEREOF, IS NOT RECOMMENDED


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED

Paramyxoviridae
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

1'-substituted carba-nucleoside analogs for antiviral treatment
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

1'substituted carba-nucleoside analogs for antiviral treatment
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods for treating Filoviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods for treating Filoviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

1'-substituted carba-nucleoside analogs for antiviral treatment
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting VEKLURY

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

NEW PATIENT POPULATION
Exclusivity Expiration: See Plans and Pricing

3-DAY DOSING REGIMEN FOR THE TREATMENT OF COVID-19 IN ADULTS AND PEDIATRIC PATIENTS (>12 YEARS AND WEIGHING AT LEAST 40 KG) WITH POSITIVE RESULTS OF DIRECT SARS-COV-2 VIRAL TESTING, WHO ARE NOT HOSPITALIZED AND HAVE MILD-TO-MODERATE COVID-19, AND ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19, INCLUDING HOSPITALIZATION OR DEATH
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc VEKLURY remdesivir SOLUTION;INTRAVENOUS 214787-002 Oct 22, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Gilead Sciences Inc VEKLURY remdesivir SOLUTION;INTRAVENOUS 214787-002 Oct 22, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Gilead Sciences Inc VEKLURY remdesivir SOLUTION;INTRAVENOUS 214787-002 Oct 22, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for VEKLURY

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Gilead Sciences Ireland UC Veklury remdesivir EMEA/H/C/005622
Veklury is indicated for the treatment of coronavirus disease 2019 (COVID 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19
Authorised no no no 2020-07-03
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for VEKLURY

When does loss-of-exclusivity occur for VEKLURY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 2467
Estimated Expiration: See Plans and Pricing

Patent: 2468
Estimated Expiration: See Plans and Pricing

Patent: 9850
Estimated Expiration: See Plans and Pricing

Australia

Patent: 15339222
Estimated Expiration: See Plans and Pricing

Patent: 15339223
Estimated Expiration: See Plans and Pricing

Patent: 18253483
Estimated Expiration: See Plans and Pricing

Patent: 19201232
Estimated Expiration: See Plans and Pricing

Patent: 20203892
Estimated Expiration: See Plans and Pricing

Patent: 21201474
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2015027413
Estimated Expiration: See Plans and Pricing

Patent: 2017007636
Estimated Expiration: See Plans and Pricing

Canada

Patent: 63832
Estimated Expiration: See Plans and Pricing

Patent: 63907
Estimated Expiration: See Plans and Pricing

Chile

Patent: 17001040
Estimated Expiration: See Plans and Pricing

Patent: 17002693
Estimated Expiration: See Plans and Pricing

China

Patent: 7073005
Estimated Expiration: See Plans and Pricing

Patent: 7074902
Estimated Expiration: See Plans and Pricing

Patent: 3549120
Estimated Expiration: See Plans and Pricing

Patent: 3620992
Estimated Expiration: See Plans and Pricing

Patent: 4191438
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 17003960
Estimated Expiration: See Plans and Pricing

Costa Rica

Patent: 170165
Estimated Expiration: See Plans and Pricing

Patent: 170483
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0181130
Estimated Expiration: See Plans and Pricing

Patent: 0200518
Estimated Expiration: See Plans and Pricing

Cuba

Patent: 170056
Estimated Expiration: See Plans and Pricing

Patent: 170145
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 20893
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 12174
Estimated Expiration: See Plans and Pricing

Patent: 66295
Estimated Expiration: See Plans and Pricing

Dominican Republic

Patent: 017000103
Estimated Expiration: See Plans and Pricing

Ecuador

Patent: 17025261
Estimated Expiration: See Plans and Pricing

Patent: 17072474
Estimated Expiration: See Plans and Pricing

El Salvador

Patent: 17005424
Estimated Expiration: See Plans and Pricing

Patent: 17005561
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 2239
Estimated Expiration: See Plans and Pricing

Patent: 9561
Estimated Expiration: See Plans and Pricing

Patent: 1790597
Estimated Expiration: See Plans and Pricing

Patent: 1790630
Estimated Expiration: See Plans and Pricing

Patent: 1990021
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 12174
Estimated Expiration: See Plans and Pricing

Patent: 12175
Estimated Expiration: See Plans and Pricing

Patent: 66295
Estimated Expiration: See Plans and Pricing

Patent: 95844
Estimated Expiration: See Plans and Pricing

Patent: 36099
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 58795
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 39231
Estimated Expiration: See Plans and Pricing

Patent: 49192
Estimated Expiration: See Plans and Pricing

Israel

Patent: 1560
Estimated Expiration: See Plans and Pricing

Patent: 1707
Estimated Expiration: See Plans and Pricing

Japan

Patent: 20484
Estimated Expiration: See Plans and Pricing

Patent: 87547
Estimated Expiration: See Plans and Pricing

Patent: 71424
Estimated Expiration: See Plans and Pricing

Patent: 57294
Estimated Expiration: See Plans and Pricing

Patent: 17186358
Estimated Expiration: See Plans and Pricing

Patent: 17533903
Estimated Expiration: See Plans and Pricing

Patent: 17534614
Estimated Expiration: See Plans and Pricing

Patent: 18172424
Estimated Expiration: See Plans and Pricing

Patent: 19048901
Estimated Expiration: See Plans and Pricing

Patent: 20090536
Estimated Expiration: See Plans and Pricing

Patent: 20097635
Estimated Expiration: See Plans and Pricing

Patent: 22065066
Estimated Expiration: See Plans and Pricing

Patent: 22068297
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 12174
Estimated Expiration: See Plans and Pricing

Patent: 66295
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 17005250
Estimated Expiration: See Plans and Pricing

Patent: 17005252
Estimated Expiration: See Plans and Pricing

Moldova, Republic of

Patent: 170046
Estimated Expiration: See Plans and Pricing

Montenegro

Patent: 070
Estimated Expiration: See Plans and Pricing

Morocco

Patent: 867
Estimated Expiration: See Plans and Pricing

Patent: 872
Estimated Expiration: See Plans and Pricing

Patent: 201
Estimated Expiration: See Plans and Pricing

Patent: 506
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 0803
Estimated Expiration: See Plans and Pricing

Patent: 0809
Estimated Expiration: See Plans and Pricing

Peru

Patent: 171439
Estimated Expiration: See Plans and Pricing

Patent: 180202
Estimated Expiration: See Plans and Pricing

Philippines

Patent: 017500631
Estimated Expiration: See Plans and Pricing

Patent: 020551055
Estimated Expiration: See Plans and Pricing

Poland

Patent: 12174
Estimated Expiration: See Plans and Pricing

Patent: 12175
Estimated Expiration: See Plans and Pricing

Patent: 66295
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 12174
Estimated Expiration: See Plans and Pricing

Patent: 12175
Estimated Expiration: See Plans and Pricing

Patent: 66295
Estimated Expiration: See Plans and Pricing

Saudi Arabia

Patent: 7381419
Estimated Expiration: See Plans and Pricing

Serbia

Patent: 425
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 202008772U
Estimated Expiration: See Plans and Pricing

Patent: 201702903T
Estimated Expiration: See Plans and Pricing

Patent: 201702904R
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 12174
Estimated Expiration: See Plans and Pricing

Patent: 12175
Estimated Expiration: See Plans and Pricing

Patent: 66295
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1800414
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1822348
Estimated Expiration: See Plans and Pricing

Patent: 2337664
Estimated Expiration: See Plans and Pricing

Patent: 2453808
Estimated Expiration: See Plans and Pricing

Patent: 170066665
Estimated Expiration: See Plans and Pricing

Patent: 170067898
Estimated Expiration: See Plans and Pricing

Patent: 170077167
Estimated Expiration: See Plans and Pricing

Patent: 210152015
Estimated Expiration: See Plans and Pricing

Spain

Patent: 74806
Estimated Expiration: See Plans and Pricing

Patent: 85034
Estimated Expiration: See Plans and Pricing

Patent: 04298
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 87432
Estimated Expiration: See Plans and Pricing

Patent: 98444
Estimated Expiration: See Plans and Pricing

Patent: 40546
Estimated Expiration: See Plans and Pricing

Patent: 67201
Estimated Expiration: See Plans and Pricing

Patent: 1629076
Estimated Expiration: See Plans and Pricing

Patent: 1630925
Estimated Expiration: See Plans and Pricing

Patent: 2039526
Estimated Expiration: See Plans and Pricing

Patent: 2115098
Estimated Expiration: See Plans and Pricing

Turkey

Patent: 1809518
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 1485
Estimated Expiration: See Plans and Pricing

Uruguay

Patent: 376
Estimated Expiration: See Plans and Pricing

Patent: 464
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VEKLURY around the world.

Country Patent Number Title Estimated Expiration
Japan 2020097635 リボシドの調製のための方法 (METHODS FOR PREPARING RIBOSIDES) See Plans and Pricing
China 114366745 治疗沙粒病毒科和冠状病毒科病毒感染的方法 (Methods of treating arenaviridae and coronaviridae virus infections) See Plans and Pricing
Brazil 112017007636 métodos para a preparação de ribosídeos See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VEKLURY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2595980 20C1065 France See Plans and Pricing PRODUCT NAME: REMDESIVIR OU UN SEL OU UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/20/1459 20200703
2595980 C202030068 Spain See Plans and Pricing PRODUCT NAME: REMDESIVIR O UNA SAL O UN ESTER FARMACEUTICAMENTE ACEPTABLES DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1459; DATE OF AUTHORISATION: 20200703; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1459; DATE OF FIRST AUTHORISATION IN EEA: 20200703
2937350 LUC00193 Luxembourg See Plans and Pricing PRODUCT NAME: REMDESIVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/20/1459 20200703
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Medtronic
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.